Delivering on the promise of precision cancer medicine

doi:10.1186/s13073-016-0373-1

Editorial

. 2016 Oct 25;8(1):110.

doi: 10.1186/s13073-016-0373-1.

Delivering on the promise of precision cancer medicine

Michael F Berger^{1

2}, Eliezer M Van Allen^{3

4}

Affiliations

¹ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. bergerm1@mskcc.org.
² Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. bergerm1@mskcc.org.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. evanallen@partners.org.
⁴ Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. evanallen@partners.org.

PMID: 27782852
PMCID: PMC5078954
DOI: 10.1186/s13073-016-0373-1

Editorial

Delivering on the promise of precision cancer medicine

Michael F Berger et al. Genome Med. 2016.

. 2016 Oct 25;8(1):110.

doi: 10.1186/s13073-016-0373-1.

Authors

Michael F Berger^{1

2}, Eliezer M Van Allen^{3

4}

Affiliations

¹ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. bergerm1@mskcc.org.
² Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. bergerm1@mskcc.org.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. evanallen@partners.org.
⁴ Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. evanallen@partners.org.

PMID: 27782852
PMCID: PMC5078954
DOI: 10.1186/s13073-016-0373-1

No abstract available

PubMed Disclaimer

Cited by

Assessing the Training and Research Environment for Genomics, Bioinformatics, and Immunology in Radiation Oncology.
Mouw KW, Beck TF, Keen JC, Dicker AP. Mouw KW, et al. JCO Clin Cancer Inform. 2018 Dec;2:1-9. doi: 10.1200/CCI.18.00045. JCO Clin Cancer Inform. 2018. PMID: 30652612 Free PMC article.
Applying Precision Oncology Principles in Radiation Oncology.
Kamran SC, Mouw KW. Kamran SC, et al. JCO Precis Oncol. 2018 May 14;2:PO.18.00034. doi: 10.1200/PO.18.00034. eCollection 2018. JCO Precis Oncol. 2018. PMID: 32914000 Free PMC article. Review.
Bioinformatics analyses of combined databases identify shared differentially expressed genes in cancer and autoimmune disease.
Sui Y, Li S, Fu XQ, Zhao ZJ, Xing S. Sui Y, et al. J Transl Med. 2023 Feb 10;21(1):109. doi: 10.1186/s12967-023-03943-9. J Transl Med. 2023. PMID: 36765396 Free PMC article.
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.
Zheng PP, Li J, Kros JM. Zheng PP, et al. Med Res Rev. 2018 Jan;38(1):325-376. doi: 10.1002/med.21463. Epub 2017 Sep 1. Med Res Rev. 2018. PMID: 28862319 Free PMC article. Review.
A Systematic Approach to Optimize the Implementation of Precision Oncology in Clinical Practice: A Meeting Proceeding.
Jazieh AR, El Rouby N, Guinigundo A, Huelsman KM, Curran E, Khan R, Grund J, Calvo AR, Claes JJ, Overton SC, Hellard S, Vasiliadis L, Liu M, Blaxall BC. Jazieh AR, et al. J Immunother Precis Oncol. 2024 Aug 19;7(3):210-216. doi: 10.36401/JIPO-23-41. eCollection 2024 Aug. J Immunother Precis Oncol. 2024. PMID: 39219991 Free PMC article. No abstract available.

See all "Cited by" articles

References

1. Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703. doi: 10.1056/NEJMoa1210093. - DOI - PMC - PubMed
1. Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8. doi: 10.1056/NEJMoa0909530. - DOI - PubMed
1. Shaw AT, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94. doi: 10.1056/NEJMoa1214886. - DOI - PubMed
1. Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. doi: 10.1056/NEJMoa062867. - DOI - PubMed
1. Van Allen EM, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20:682–8. doi: 10.1038/nm.3559. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Substances

Actions
Actions

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703. doi: 10.1056/NEJMoa1210093. - DOI - PMC - PubMed

[2] Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703. doi: 10.1056/NEJMoa1210093. - DOI - PMC - PubMed

[3] Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8. doi: 10.1056/NEJMoa0909530. - DOI - PubMed

[4] Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8. doi: 10.1056/NEJMoa0909530. - DOI - PubMed

[5] Shaw AT, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94. doi: 10.1056/NEJMoa1214886. - DOI - PubMed

[6] Shaw AT, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94. doi: 10.1056/NEJMoa1214886. - DOI - PubMed

[7] Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. doi: 10.1056/NEJMoa062867. - DOI - PubMed

[8] Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. doi: 10.1056/NEJMoa062867. - DOI - PubMed

[9] Van Allen EM, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20:682–8. doi: 10.1038/nm.3559. - DOI - PMC - PubMed

[10] Van Allen EM, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20:682–8. doi: 10.1038/nm.3559. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Delivering on the promise of precision cancer medicine

Affiliations

Delivering on the promise of precision cancer medicine

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources